ClinicalTrials.gg
CompletedNCT01934361Updated Dec 9, 2020

Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme

A Phase 1 interventional study of buparlisib and carboplatin in Recurrent Glioblastoma Multiforme, sponsored by Novartis Pharmaceuticals. Completed at 14 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2016, 10 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing lomustine in Glioblastoma — 3 open to participants now, 4 under way, 2 of them phase 3. Lomustine · Glioblastoma.

Enrollment
15th of 22
35 · median 68
Started
2014
with 1 other
Phase 1
4 of 22
1 open now
Registered
12th of 22
by date

Among the 22 studies testing lomustine in Glioblastoma, this one is the 15th largest by enrollment, is one of 2 that started in 2014, is one of 4 in phase 1, and was the 12th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

3 of the 22 studies testing lomustine in Glioblastoma are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About lomustine

Lomustine: first FDA approval 1976 (GLEOSTINE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing lomustine in Glioblastoma, or all of them as a file.
02

Study summary

This is a multi-center, phase Ib/ II study (two parts) with patients that had recurrent glioblastoma multiforme. The first part (phase Ib) was to investigate the maximum tolerated dose/Recommended phase ll dose (MTD/RP2D) of once daily buparlisib in combination with every-three-week carboplatin or buparlisib once daily in combination with every-six-week lomustine (CCNU) using a Bayesian model. Once MTD/ RP2D is established in either of the 2 arms, the corresponding phase II portion of the study was to start. Phase II was to assess the treatment effect of buparlisib in combination with carboplatin in terms of Progression Free Survival (PFS) and was to compare the treatment effect of buparlisib with lomustine versus lomustine plus placebo in terms of PFS.

A preliminary assessment for both combinations (buparlisib plus carboplatin or lomustine) demonstrated that there was not enough antitumor activity compared to historical data with single agent carboplatin or lomustine. Based on the overall safety profile, and preliminary anti-tumor activity observed in this study, Novartis decided that no additional patients would be enrolled into this study. As a consequence, the Phase II part of the study was not conducted.

03

Conditions studied

  • Recurrent Glioblastoma Multiforme

Browse trials for

Keywords

  • BKM120
  • Recurrent glioblastoma multiforme
  • rGBM
  • buparlisib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is an adult ≥ 18 years old at the time of .
  • Patient has confirmed diagnosis of GBM with documented recurrence after treatment including radiotherapy and TMZ (SoC), not suitable for curative surgery or re-irradiation.
  • Patient has at least one measurable and/or non- as per RANO criteria
  • Patient has recovered (to Grade ≤1) from all toxicities related to prior antineoplastic therapies.
  • Patient has performance status (KPS) ≥70%.
  • Patient has adequate organ and bone marrow functions:

    • Absolute Neutrophils Count (ANC) ≥ 1.5 x 109/L
    • ≥ 100 x 109/L (in case of transfusion stable for ≥14 days prior to treatment start)
    • ≥ 9.0 g/dL (in case of transfusion stable for ≥14 days prior to treatment start)
    • ≤ 1,5
    • Serum Creatinine ≤ 1.5 x , or > 45mL/min
    • Potassium and calcium (corrected for albumin), sodium and magnesium within institutional normal limits
    • Serum ≤ ULN, and ALT ≤ ULN
    • ≤ 8%
    • Fasting plasma glucose (FPG) ≤ 120 mg/dL or ≤ 6.7 mmol/L
  • Patient has tumor tissues available (archival or fresh).

Exclusion criteria

Exclusion Criteria:

  • Patient has received previous treatment with PI3K inhibitors, lomustine or carboplatin.
  • Patient has received previous antineoplastic treatment for recurrent GBM (e.g. VEGF inhibitors, cytotoxic agents).
  • Patient has received more than one line of cytotoxic chemotherapy
  • Patient has concurrent use of anti-neoplastic agents including therapy
  • Patient is currently receiving warfarin or other coumarin derived anti-coagulant, for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin (LMWH), or fondaparinux is allowed.
  • Patient is currently receiving treatment with drugs known to be moderate or strong inhibitors or inducers of isoenzyme . The patient must have discontinued strong inducers for at least one week and must have discontinued strong inhibitors before the treatment is initiated. Switching to a different medication prior to randomization is allowed.
  • Patient is currently receiving an enzyme-inducing anti-epileptic drug (EIAED). The patient must have discontinued EIAED therapy for at least two weeks prior to starting study drug.

Other protocol-defined Inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Lomustine+ buparlisib (Phase Ib)

    Drug: buparlisib · Drug: lomustine

  • Experimental
    carboplatin+ buparlisib (Phase Ib)

    Drug: buparlisib · Drug: carboplatin

  • Experimental
    lomustine+ buparlisib (Phase II)

    Drug: buparlisib · Drug: lomustine

  • Placebo comparator
    lumustine + placebo (Phase II)

    Drug: lomustine · Drug: placebo

  • Experimental
    carboplatin+ buparlisib (Phase II)

    Drug: buparlisib · Drug: carboplatin

Interventions

  • Buparlisib administered orally on a continuous daily schedule. Buparlisib is manufactured as 10mg and 50mg hard gelatin capsules.

  • Carboplatin intravenous infusion will be administered at a dose of AUC 5 in a 21 day cycle (every 3 weeks).

  • Lomustine will be administered as a single oral dose of 100 mg/m² every 6 weeks in a 42 day cycles.

  • Drugplacebo

    Placebo will be administered orally on a continuous QD dosing schedule for cycles of 42 days. Buparlisib matching placebo is manufactured as 10 mg and 50 mg hard gelatin capsules.

06

What researchers measure

Primary outcomes

  1. Number of Total Dose-limiting Toxicity (DLT) during Dose Escalation part to determine Maximum Tolerated Dose (MTD) [Phase Ib]

    Maximum Tolerated Dose (MTD) is defined as the highest BKM120 dosage that does not cause medically unacceptable Dose Limiting Toxicities (DLTs) in more than 35% of the treated patients during the first cycle of treatment. DLT is defined as treatment-related toxicity occurring during the phase Ib cycle 1 and meeting specific protocol-predefined criteria. The information will be integrated in a Bayesian logistic regression model with overdose control to estimate the MTD.

    Time frame: Cycle 1 (21 days carboplatin combination or 42 days lomustine combination )

  2. 12 week Progression Free Survival (PFS) rate (Phase II- Carboplatin combination)

    12-week Progression Free Survival (PFS) is defined as the percentage of patients who are progression free 12 weeks after the date of the start of the treatment ("success"). Patients who progressed, died or discontinued within the 12 weeks of observation are counted as "failure".

    Time frame: 12 weeks

  3. Progression Free Survival (PFS) [phase II lomustine combinations]

    Progression Free Survival (PFS) is defined as the time from date of randomization to the date of the event, which is the first radiologically documented disease progression \[per local investigator assessment according to Response Assessment in Neuro-Oncology (RANO) criteria\] or death due to any cause.

    Time frame: Randomization until date of the event (expected average 3 months).

Secondary outcomes

  1. Frequency and severity of Adverse Events (AEs) [Phase Ib, Phase II, all treatment arms]

    The incidence of Adverse Events (AEs) summarized by system organ class and or preferred term, severity (based on Common Terminology Criteria for Adverse Events (CTCAE) grades version 4), type of AE, relation to study treatment.

    Time frame: Until 30 days after treatment discontinuation

  2. Overall Response Rate (ORR) as per Response Assessment in Neuro-Oncology (RANO) [Phase Ib , both combinations]

    Overall response rate (ORR) is defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR), based on the investigator assessment as per Response Assessment in Neuro-Oncology (RANO) criteria.

    Time frame: Baseline, every 6 weeks from treatment start until disease progression or until start of another antineoplastic treatment or death which ever occurs first up to 1 year

  3. Progression Free Survival (PFS) [Phase Ib- both combinations]

    Progression Free Survival (PFS) is defined as time from date of treatment start to the date of the event, which is the first radiologically documented disease progression or death due to any cause per local investigator assessment.

    Time frame: Time from treatment start to the date of the event (expected average 3 months)

  4. Overall response rate (ORR) [Phae II, carboplatin combination]

    Overall response rate (ORR) is defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR), based on the investigator assessment as per Response Assessment in Neuro-Oncology (RANO) criteria.

    Time frame: Baseline, every 6 weeks from treatment start until disease progression or until start of another antineoplastic treatment or death which ever occurs first up to 1 year

  5. Progression Free Survival (PFS) [Phase II, carboplatin combination]

    Progression Free Survival (PFS) is defined as time from date of treatment start to the date of the event, which is the first radiologically documented disease progression or death due to any cause per local investigator assessment.

    Time frame: Time from treatment start to the date of the event (Expected average: 3 months)

  6. 24 week Progression Free Survival (PFS) rate (Phase II carboplatin combination)

    24 weeks Progression Free Survival (PFS) is defined as the percentage of patients who are progression free 24 weeks after the date of the start of the treatment ("success"). Patients who progressed, died or discontinued within the 24 weeks of observation are counted as "failure".

    Time frame: 24 weeks

  7. Overall Survival (OS) (Phase II Carboplatin combination)

    Overall survival (OS) is defined as the time from the date of randomization for buparlisib + lomustine / placebo + lomustine Phase II, or the time from the first study drug intake for buparlisib + carboplatin Phase II, to the date of death due to any cause.

    Time frame: 12 months

  8. Overall Response Rate (ORR) (Phase II Lomustine combinations)

    Overall response rate (ORR) is defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR), based on the investigator assessment as per Response Assessment in Neuro-Oncology (RANO) criteria.

    Time frame: Baseline, every 6 weeks from treatment start until disease progression or until start of another antineoplastic treatment or death which ever occurs first up to 1 year

  9. 12 week Progression Free Survival (PFS) rate (Phase II- lomustine combinations)

    12-week Progression Free Survival (PFS) is defined as the percentage of patients who are progression free 12 weeks after the date of the start of the treatment ("success"). Patients who progressed, died or discontinued within the 12 weeks of observation are counted as "failure".

    Time frame: 12 weeks

  10. 24 week Progression Free Survival (PFS) rate (Phase II- lomustine combinations)

    24 weeks Progression Free Survival (PFS) is defined as the percentage of patients who are progression free 24 weeks after the date of the start of the treatment ("success"). Patients who progressed, died or discontinued within the 24 weeks of observation are counted as "failure".

    Time frame: 24 weeks

  11. Overall survival (OS) [Phase II lomustine combinations]

    Overall survival (OS) is defined as the time from the date of randomization for buparlisib + lomustine / placebo + lomustine Phase II, or the time from the first study drug intake for buparlisib + carboplatin Phase II, to the date of death due to any cause.

    Time frame: 12 months

07

Study locations

14 sites
  • Barrow Neurological Insitute St. Joseph's Hospital
    Phoenix, Arizona 85013, United States
  • Highlands Oncology Group
    Fayetteville, Arkansas 72703, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • MD Anderson Cancer Center/University of Texas
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    Heidelberg, Victoria 3084, Australia
  • Novartis Investigative Site
    Parkville, Victoria 3050, Australia
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Toronto, Ontario M5G 1Z6, Canada
  • Novartis Investigative Site
    Marseille Cedex 05, 13885, France
  • Novartis Investigative Site
    Paris Cedex 13, 75651, France
  • Novartis Investigative Site
    Saint Herblain cedex, 44805, France
  • Novartis Investigative Site
    Barcelona, Catalunya 08036, Spain
  • Novartis Investigative Site
    Hospitalet de LLobregat, Catalunya 08907, Spain
08

References and documents

Publications

  • Rosenthal M, Clement PM, Campone M, Gil-Gil MJ, DeGroot J, Chinot O, Idbaih A, Gan H, Raizer J, Wen PY, Pineda E, Donnet V, Mills D, El-Hashimy M, Mason W. Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study. ESMO Open. 2020 Jul;5(4):e000672. doi: 10.1136/esmoopen-2020-000672. PubMed 32665311 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2014 to primary completion in Jul 2016, 28 months.

Of 82 industry-sponsored phase 1 interventional studies under Glioblastoma, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 64. This study's 28 months is below that.

Counting every sponsor, half of 321 studies reached it within 44 months; a quarter within 29 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2013
First posted
Sep 4, 2013
StartActual
Feb 28, 2014
Primary completionActual
Jul 7, 2016
CompletionActual
Jul 7, 2016
Last update
Dec 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01934361
Responsible party
Sponsor
First posted
Sep 4, 2013
Start date
Feb 28, 2014
Primary completion
Jul 7, 2016
Completion
Jul 7, 2016
Last update
Dec 9, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Buparlisib · Lomustine

Start the discussion